SoftOx Solutions AS (FRA:6FV)

Market Cap	25.97M +214.9%
Revenue (ttm)	1.32M +96.9%
Net Income	-913.57K
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	2,255
Open	0.0040
Previous Close	0.0100
Day's Range	0.0040 - 0.0040
52-Week Range	0.0030 - 0.0500
Beta	n/a
RSI	57.07
Earnings Date	Mar 25, 2026

About SoftOx Solutions AS

SoftOx Solutions AS, together with its subsidiaries, operates as a clinical-stage pharmaceutical company that develops antimicrobials products for infection prevention and treatment in Norway. The company develops SoftOx Inhalation Solution, an inhalation solution that is phase II clinical trial for the treatment of ventilator associated pneumonia and other airway infections. It also developing pan antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi. SoftOx Solutions AS was founded in 2012 and is headquartered in Fornebu, Norwa...

• Industry: Pharmaceutical Preparations
• Founded: 2012
• Employees: 2
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6FV

Financial Performance

In 2025, SoftOx Solutions AS's revenue was 15.58 million, an increase of 96.92% compared to the previous year's 7.91 million. Losses were -10.81 million, -74.82% less than in 2024.

Financial numbers in NOK